Media Articles Related to Zarontin (Ethosuximide)
Updated epilepsy classification may lead to advances in diagnosis, treatment, and research
Source: Epilepsy News From Medical News Today [2017.03.10]
It has been nearly three decades since experts published a classification system related to epilepsy.
Modified Atkins diet helps children with rare form of epilepsy
Source: Epilepsy News From Medical News Today [2017.02.24]
Doose syndrome or myoclonic-astatic epilepsy is a rare syndrome accounting for one to two percent of childhood epilepsies.
Significant epilepsy gene discovery in dogs
Source: Epilepsy News From Medical News Today [2017.02.22]
Researh groups from the University of Helsinki, the LMU Munich and the University of Guelph have described in collaboration a novel myoclonic epilepsy in dogs and identified its genetic cause.
Epilepsy drug discovered in fish model shows promise in small pediatric clinical trial
Source: Clinical Trials / Drug Trials News From Medical News Today [2017.02.13]
"Bench-to-bedside" describes research that has progressed from basic science in animal models that has led to therapies used in patients.
Many older adults with epilepsy may not be receiving optimal care
Source: Epilepsy News From Medical News Today [2017.02.10]
Many older adults with newly diagnosed epilepsy in the United States are being prescribed older anti-epileptic drugs (AEDs), and only half begin treatment with AEDs within the first 30 days of a...
Published Studies Related to Zarontin (Ethosuximide)
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. [2010.03.04]
BACKGROUND: Childhood absence epilepsy, the most common pediatric epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and tolerable initial empirical treatment has not been defined... CONCLUSIONS: Ethosuximide and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilepsy. Ethosuximide is associated with fewer adverse attentional effects. (ClinicalTrials.gov number, NCT00088452.) 2010 Massachusetts Medical Society
Effect of intracranial administration of ethosuximide in rats with spontaneous or pentylenetetrazol-induced spike-wave discharges. [2011.07]
PURPOSE: Generalized absence seizures are characterized by bilateral spike-wave discharges (SWDs), particularly in the frontoparietal cortical region. In WAG/Rij and GAERS rats with absence epilepsy, recent evidence indicates that SWDs arise first from the lateral somatosensory cortex (LSC), that is, the cortical focus theory...
Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. [2010.08]
PURPOSE: Epilepsy is a heterogeneous syndrome characterized by recurrent, spontaneous seizures; continuous medication is, therefore, necessary, even after the seizures have long been suppressed with antiepileptic drug (AED) treatments. The most disturbing issue is the inability of AEDs to provide a persistent cure, because these compounds generally suppress the occurrence of epileptic seizures without necessarily having antiepileptogenic properties...
Ethosuximide converts ictogenic neurons initiating absence seizures into normal neurons in a genetic model. [2009.07]
Absence epilepsy is a form of generalized epilepsy commonly seen in children. The neuronal process by which ethosuximide (ETX), a first choice anti-absence drug, prevents absence seizures is still unresolved...
Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves. [2008.11]
The aim of this study was to characterize the interaction between tiagabine (TGB) and ethosuximide (ETS), two antiepileptic drugs, in pentylenetetrazole (PTZ)-induced clonic seizures in mice using isobolographic analysis. The nature of the interaction between the drugs administered in combination was ascertained by estimating plasma and brain concentrations of ETS and TGB using fluorescence polarization immunoassay (FPIA) and high-performance liquid chromatography (HPLC)...
Reports of Suspected Zarontin (Ethosuximide) Side Effects
Drug Ineffective (3),
Poor Quality Drug Administered (3),
Mycoplasma Infection (2),
Abdominal Discomfort (2),
Stevens-Johnson Syndrome (2),
Oral Infection (2),
Toxic Epidermal Necrolysis (2), more >>